Merck’s MET inhibitor tepotinib gains positive opinion from MHRA
The positive opinion has been issued via the MHRA’s early access the medicine (EAMS) scheme
Read More
Tag: Tepotinib
EU to review Merck’s targeted lung cancer drug
Tepotinib could be the first treatment on the market for NSCLC in adults harbouring METex14 skipping alterations
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
